NextCure (NXTC) Assets Average (2019 - 2026)
NextCure (NXTC) posted quarterly Assets Average of $44.1 million for Q1 2026, down 40.43% year-over-year from $74.0 million in Q1 2025, and down 1.82% quarter-over-quarter from $44.9 million in Q4 2025.
NextCure (NXTC) Assets Average (2019 - 2026) Analysis & Trends
NextCure's Assets Average history runs 8 years deep, the most recent figure standing at $44.1 million for Q1 2026.
- In Q1 2026, Assets Average fell 40.43% year-over-year to $44.1 million; the TTM figure through Mar 2026 stood at $44.1 million (down 40.43% YoY), while the FY2025 annual figure was $65.5 million, down 37.27% from the prior year.
- Assets Average for Q1 2026 stood at $44.1 million, down from $44.9 million in the prior quarter.
- The five-year high for Assets Average was $232.6 million in Q1 2022, with the low at $43.7 million in Q3 2025.
- The 5-year median for Assets Average is $121.6 million (2024), against an average of $125.1 million.
- The sharpest annual moves came in 2022 and 2025: Assets Average retreated 22.17% in 2022, then slumped 54.75% in 2025.
- NextCure's Assets Average stood at $187.0 million in 2022, then decreased by 28.36% to $134.0 million in 2023, then sank by 36.11% to $85.6 million in 2024, then plunged by 47.55% to $44.9 million in 2025, then decreased by 1.82% to $44.1 million in 2026.
- Business Quant data shows NXTC's Assets Average at $44.1 million in Q1 2026, $44.9 million in Q4 2025, and $43.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | 30.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.30 Mn |
| Mar 31, 2026 | 44.08 Mn |
| Dec 31, 2025 | 44.90 Mn |
| Sep 30, 2025 | 43.65 Mn |
| Jun 30, 2025 | 57.41 Mn |
| Mar 31, 2025 | 74.00 Mn |
| Dec 31, 2024 | 85.60 Mn |
| Sep 30, 2024 | 96.47 Mn |
| Jun 30, 2024 | 108.87 Mn |
| Mar 31, 2024 | 121.60 Mn |
| Dec 31, 2023 | 133.99 Mn |
| Sep 30, 2023 | 146.66 Mn |
| Jun 30, 2023 | 160.59 Mn |
| Mar 31, 2023 | 175.98 Mn |
| Dec 31, 2022 | 187.04 Mn |
| Sep 30, 2022 | 198.14 Mn |
| Jun 30, 2022 | 214.56 Mn |
| Mar 31, 2022 | 232.57 Mn |
| Dec 31, 2021 | 250.11 Mn |
| Sep 30, 2021 | 266.59 Mn |